文献速递湿疹皮炎与荨麻疹

Benralizumab对慢性自发性荨麻疹无效:IIb期ARROYO试验结果

Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial.
PubMed 文献 · Br J Dermatol · 2024-01-01

ARROYO试验IIb期部分纳入155例抗组胺药治疗后仍有症状的慢性自发性荨麻疹(CSU)成人患者,随机接受Benralizumab 30mg、60mg或安慰剂治疗24周。第12周时,Benralizumab组与安慰剂组在瘙痒严重程度评分(ISS7)和荨麻疹活动度评分(UAS7)变化上均无显著差异,尽管血嗜酸性粒细胞近完全耗竭,未见临床获益。

要点

  • Benralizumab虽可近完全耗竭血嗜酸性粒细胞,但对CSU症状无显著改善。
  • 第12周ISS7和UAS7变化在Benralizumab与安慰剂间均无统计学差异。
  • 安全性与Benralizumab已知特征一致,无新安全信号。

核心结论

  • Benralizumab在抗组胺药治疗后仍有症状的CSU患者中未显示优于安慰剂的临床疗效。

研究设计与样本

  • ARROYO试验为24周随机双盲安慰剂对照IIb期研究,纳入155例正在接受H1抗组胺药治疗的CSU成人患者。
  • 患者随机分配至五个治疗组,包括Benralizumab 30mg组59例、60mg组56例和安慰剂组40例。

主要发现

  • 第12周ISS7较基线变化:Benralizumab 30mg vs 安慰剂最小二乘均数差-1.01(95%CI -3.28至1.26);60mg vs 安慰剂-1.79(95%CI -4.09至0.50)。
  • 第12周UAS7较基线变化:Benralizumab 30mg vs 安慰剂P=0.407;60mg vs 安慰剂P=0.082。
  • 第24周观察到Benralizumab治疗患者血嗜酸性粒细胞水平耗竭。
  • 所有其他次要终点及探索性/亚组分析均显示Benralizumab与安慰剂无显著差异。
  • 安全性结果与Benralizumab已知特征一致。

临床怎么用

  • 对于抗组胺药控制不佳的CSU患者,不应基于嗜酸性粒细胞耗竭机制选用Benralizumab。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic spontaneous urticaria (CSU) is a relatively common skin disease associated with hives and angio-oedema. Eosinophils play a role in CSU pathogenesis. Benralizumab, an anti-interleukin-5 receptor-α monoclonal antibody, has been shown to induce nearly complete depletion of eosinophils. OBJECTIVES: To determine the clinical efficacy and safety of benralizumab in patients with CSU who were symptomatic despite H1 antihistamine treatment. METHODS: The 24-week, randomized, double-blind, placebo-controlled, phase IIb portion of the ARROYO trial enrolled adult patients with CSU who were currently on H1 antihistamine treatment. Patients were randomized to one of five treatment groups according to benralizumab dose and regimen for a 24-week treatment period. The primary endpoint was change from baseline in Itch Severity Score (ISS)7 at week 12. The key secondary endpoint was change from baseline in Urticaria Activity Score (UAS)7 at week 12. Additional secondary endpoints included other metrics to assess CSU at week 24, blood eosinophil levels, and pharmacokinetics and immunogenicity assessments. Exploratory subgroup analyses were conducted to explore responses according to demographics, clinical features and biomarkers. Safety was assessed in all treatment groups. RESULTS: Of 155 patients, 59 were randomized to benralizumab 30 mg, 56 to benralizumab 60 mg and 40 to placebo. Baseline and disease characteristics were consistent with what was expected for patients with CSU. There were no significant differences in change from baseline in ISS7 score at week 12 between benralizumab and placebo [benralizumab 30 mg vs. placebo, least-squares mean difference -1.01, 95% confidence interval (CI) -3.28 to 1.26; benralizumab 60 mg vs. placebo, least-squares mean difference -1.79, 95% CI -4.09 to 0.50] nor in change from baseline in UAS7 score at week 12 between benralizumab and placebo (benralizumab 30 mg vs. placebo, P = 0.407; benralizumab 60 mg vs. placebo, P = 0.082). Depletion of blood eosinophil levels was observed at week 24 in patients treated with benralizumab. All other secondary endpoints and exploratory/subgroup analyses indicated no significant differences between benralizumab and placebo. Safety results were consistent with the known profile of benralizumab. CONCLUSIONS: Although benralizumab resulted in near-complete depletion of blood eosinophils, there was no clinical benefit over placebo. Chronic spontaneous urticaria (CSU) is a common disease characterized by hives, itching and inflammation (swelling) of the skin. CSU is mainly driven by what we call ‘mast cells’. ‘Eosinophils’ are a type of white blood cell that protect the body from infections and allergens. These cells are abundant in skin biopsy samples of people with CSU, especially in the hives that contribute to swelling. Therefore, we thought that reducing eosinophils would be beneficial for treating CSU. Benralizumab is a drug that has been shown to reduce eosinophils in other diseases. This study, called ‘ARROYO’, was a 24-week clinical trial that compared benralizumab treatment with a placebo (inactive medicine) in adults with CSU who were taking antihistamines. We aimed to determine whether benralizumab would improve symptoms of CSU over time. Several assessments were used to measure changes in CSU symptoms, including hives, severity of itchiness, swelling of the skin, and other aspects related to overall psychological and physical wellbeing. The characteristics of the 155 people who took part in this study were consistent with what was expected for patients with CSU. We found that while benralizumab reduced eosinophil levels in people with CSU, there were no differences in symptoms in people receiving benralizumab compared with those receiving placebo. There were no new safety concerns related to benralizumab and no deaths. Overall, although benralizumab is effective at reducing the number of eosinophils, it is not effective at treating the symptoms of CSU. More studies are needed to uncover potential treatment targets in CSU.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Altrichter S, Giménez-Arnau AM, Bernstein JA, et al. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial. Br J Dermatol. 2024. PMID: 38367194. doi:10.1093/bjd/ljae067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。